A two-phase composition comprising: a first phase comprising a base nutritive medium; and a second phase comprising nanoparticles that comprise an outer lipophilic coating and an inner hydrophilic core, wherein a) the first phase comprises physiologically compatible concentrations of water soluble or dispersible nutrients, and physiological salts; b) the nanoparticles of the second phase comprise lipids, fatty acids, sterols and free fatty acids, and c) the two-phase composition has an osmolality of at least about 300 mOsM/kg, and wherein the nanoparticles have a mean diameter ranging from about 100 nm to about 300 nm, and wherein the hydrophilic inner core of the nanoparticles contains a solution or suspension comprising a moiety capable of binding and releasing oxygen, characterised in that: said first phase is a composition comprising: (i) the components shown by Tables 1, 2A, 2B, 2C and 3 (Premix I of Formula I), or (ii) the components shown by Tables 6, 7A, 7B, 7C and 8 (Premix I of Formula II), based on a final total volume of 1 liter for combined first and second phase, and said second phase is a composition comprising: (iii) the components shown by Table 4, as emulsified through a microfluidizer (Premix II of Formula I), or (iv) the components shown by Tables 9 and 10, as emulsified through a microfluidizer (Premix II of Formula II), wherein the said first phase (Premix I of Formula I or Formula II) is combined with said second phase (Premix II of Formula I or Formula II) to provide said two-phase composition. a first phase comprising a base nutritive medium; and a second phase comprising nanoparticles that comprise an outer lipophilic coating and an inner hydrophilic core, wherein a) the first phase comprises physiologically compatible concentrations of water soluble or dispersible nutrients, and physiological salts; b) the nanoparticles of the second phase comprise lipids, fatty acids, sterols and free fatty acids, and c) the two-phase composition has an osmolality of at least about 300 mOsM/kg, and a) the first phase comprises physiologically compatible concentrations of water soluble or dispersible nutrients, and physiological salts; b) the nanoparticles of the second phase comprise lipids, fatty acids, sterols and free fatty acids, and c) the two-phase composition has an osmolality of at least about 300 mOsM/kg, and wherein the nanoparticles have a mean diameter ranging from about 100 nm to about 300 nm, and wherein the hydrophilic inner core of the nanoparticles contains a solution or suspension comprising a moiety capable of binding and releasing oxygen, characterised in that: said first phase is a composition comprising: (i) the components shown by Tables 1, 2A, 2B, 2C and 3 (Premix I of Formula I), or (ii) the components shown by Tables 6, 7A, 7B, 7C and 8 (Premix I of Formula II), (i) the components shown by Tables 1, 2A, 2B, 2C and 3 (Premix I of Formula I), or (ii) the components shown by Tables 6, 7A, 7B, 7C and 8 (Premix I of Formula II), based on a final total volume of 1 liter for combined first and second phase, and said second phase is a composition comprising: (iii) the components shown by Table 4, as emulsified through a microfluidizer (Premix II of Formula I), or (iv) the components shown by Tables 9 and 10, as emulsified through a microfluidizer (Premix II of Formula II), (iii) the components shown by Table 4, as emulsified through a microfluidizer (Premix II of Formula I), or (iv) the components shown by Tables 9 and 10, as emulsified through a microfluidizer (Premix II of Formula II), wherein the said first phase (Premix I of Formula I or Formula II) is combined with said second phase (Premix II of Formula I or Formula II) to provide said two-phase composition.